The most widely studied tissue markers in CRC are thymidylate synthase, microsatellite instability, p53, K-ras and deleted in colorectal cancer (DCC), but they have not currently been recommended in routine practice for determining prognosis or predicting response to therapy [ 4].
On the basis of these findings, we conclude that sequencing and copy number analysis of both PAX3 and MITF have to be recommended in the routine molecular diagnostic setting for patients, WS1 and WS2.
Health Related Quality of Life questionnaires are frequently used for research, however only recently has their use been recommended in the routine clinical management of pituitary patients.
None of the GP IIb/IIIa antagonists are recommended in the routine management of low-risk, troponin-negative patients in whom early angiography is not intended.
In addition to the FEV1, also MRC functional dyspnoea has proved to be useful in predicting outcomes in patients with COPD, thus MRC functional dyspnoea measurement is recommended in the routine handling and evaluation of these patients [ 1].
MRC functional dyspnea is now proven to be useful in predicting outcomes in patients with COPD and is recommended in the routine handling and evaluation of these patients [ 19].
Proteomics-based identification of amyloid is recommended in cases where routine immunofluorescence and/or immunohistochemical testing cannot definitively type the amyloid deposits (Table 1) [ 4, 7].
